Aminoglycoside treatment and renal prostaglandin excretion in premature infants.
During prospective studies of indomethacin treatment of symptomatic patent ductus arteriosus, the question arose whether aminoglycosides alter renal prostaglandin metabolism. Adopting the matched-pair method, we retrospectively analyzed creatinine clearances, urine output and renal PGE2 and PGF2 alpha excretion in preterm infants with and without aminoglycosides. No consistent differences of any of these parameters within the matched pairs could be demonstrated. Indomethacin induced comparable reductions of creatinine clearances in patients with and without aminoglycoside pretreatment. Discrepancies with animal studies and clinical implications of these results are discussed.
D000328:Adult; D000617:Aminoglycosides / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003404:Creatinine / Q000652:urine; D015237:Dinoprost; D015232:Dinoprostone; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy* / Q000652:urine; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007231:Infant, Newborn; D007234:Infant, Premature; D011247:Pregnancy; D011292:Premedication; D011453:Prostaglandins / Q000652:urine*; D011458:Prostaglandins E / Q000652:urine; D011460:Prostaglandins F / Q000652:urine; D014031:Tobramycin / Q000009:adverse effects
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; D003404:Creatinine; D015237:Dinoprost; D015232:Dinoprostone; D014031:Tobramycin; D007213:Indomethacin